Sutro Biopharma, Inc.: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Mar 16, 2020 and accepted by EDGAR at Mar 13, 2020, 18:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2019-01-01 to 2019-12-31 | $42.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2019-01-01 to 2019-12-31 | $65.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$55.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2019-01-01 to 2019-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-10-01 to 2019-12-31 | −$14.8m | us-gaap:NetIncomeLoss |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$55.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | −$0.65 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −$2.43 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | −$65.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2019-12-31 | $5.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $128.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $156.4m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $33.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $58.6m | us-gaap:Liabilities |
| Long-term debt | At period end2019-12-31 | $8.9m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-12-31 | $1.0m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2019-12-31 | $97.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-010890. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.